Intelligence Β· Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe β grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring β€24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months β use filters for patent-cliff planning.
-
US 6326466
Double-stranded RNA dependent protein kinase derived peptides to promote proliferation of cells and tissues in a controlled manner
expired -
US 6323325
Agents that bind to and inhibit human cytochrome P450 2A6
expired -
US 6322809
Liposomes containing particulate materials
expired -
US 6323185
Anti-viral guanosine-rich oligonucleotides and method of treating HIV
expired -
US 6322780
Marek's disease virus vaccines for protection against Marek's disease
expired -
US 6319687
Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
expired -
US 6320022
Adrenomedullin peptides
expired -
US 6319496
Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
expired -
US 6316197
Method of diagnosing of exposure to toxic agents by measuring distinct pattern in the levels of expression of specific genes
expired -
US 6316423
Method of treating ischemic, hypoxic and anoxic brain damage
expired -
US 6316190
Oligonucleotides which specifically bind retroviral nucleocapsid proteins
expired -
US 6316000
Cloning and expression of plasmodium falciparum transmission-blocking target antigen, PFS230
expired -
US 6313090
Methods for treating parasitic infection using thiopeptides
expired -
US 6312944
Pneumococcal fimbrial protein A
expired -
US 6313098
Methods of neuroendocrine regulation of affective disorders
expired -
US 6310064
Aralkyl diazabicycloalkane derivatives for CNS disorders
expired -
US 6310046
Sequestrin of Plasmodium falciparum
expired -
US 6309650
Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
expired -
US 6309631
Barrier cream
expired -
US 6309669
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
expired -
US 6307090
Acylated oligopeptide derivatives having cell signal inhibiting activity
expired -
US 6303130
Pasteurella haemolytica vaccine inactivated by ultraviolet light
expired -
US 6303604
Pharmaceutical composition comprising 2,4-diamino-6-benzyloxy-s-triazine and inactivation of O6-alkylguanine-DNA-alkyltransferase
expired -
US 6296879
Ruminal fluid inoculation of calves
expired -
US 6296854
Live attenuated Venezuelan Equire encephalitis vaccine
expired -
US 6294322
Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
expired -
US 6291664
Method of eliminating inhibitory/instability regions of mRNA
expired -
US 6290963
Anti-HIV compositions containing native and recombinant peptides
expired -
US 6290981
Use of nitric oxide-releasing agents to treat impotency
expired -
US 6287566
Protective peptides neurotoxin of C. botulinum
expired -
US 6287562
Methods of inhibiting the growth of cells bearing LewisY antigens using B1, B3, or B5 targeted immunoconjugates
expired -
US 6287759
Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
expired -
US 6284254
Immunogenic compositions comprising cold-adapted attenuated respiratory syncytial virus mutants
expired -
US 6284491
Biologically active synthetic thyrotropin and cloned gene for producing same
expired -
US 6280734
Simian-human HAV having a chimeric 2C protein
expired -
US 6277980
Human papilloma virus inhibition by anti-sense oligonucleotides
expired -
US 6277379
Use of purified invaplex from gram negative bacteria as a vaccine
expired -
US 6277973
Cloning and expression of a DNA sequence encoding a 41 kDa cryptosporidium parvum oocyst wall protein
expired -
US 6274598
Methods for treating antibiotic-resistant infections
expired -
US 6274611
Methods and compositions for inhibition of viral replication
expired -
US 6270779
Nitric oxide-releasing metallic medical devices
expired -
US 6270778
Melanoma antigens and their use in diagnostic and therapeutic methods
expired -
US 6268383
Substituted aromatic compounds for treatment of antibiotic-resistant infections
expired -
US 6265160
Method of identifying inhibitors of the Jak-Stat signal transduction pathway
expired -
US 6264957
Product of infectious respiratory syncytial virus from cloned nucleotide sequences
expired -
US 6261831
Ultra-wide band RF-enhanced chemotherapy for cancer treatmeat
expired -
US 6261570
Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
expired -
US 6261790
Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies
expired
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory